




(GBM) is the most frequent and 
aggressive primary malignant 
brain tumor in adults, with a me-
dian overall survival (OS) between 
10 and 20 months [1]. The vast 
majority of patients with GBM 
experience recurrent disease, with 
a median time to recurrence of 
7 months [2]. Surgery, temozolo-
mide (TMZ), and fractionated ra-
diotherapy are standards of care 
for newly diagnosed GBM [3]. 
However, the approach for GBM 
recurrence is considerably more 
heterogenous [4]. Options include 
repeated surgery, chemotherapy, 
bevacizumab (BEV), experimental 
agents, or re-irradiation. Numer-
ous re-irradiation strategies exist, 
including conventional fraction-
ated external beam radiotherapy 
(EBRT), fractionated stereotactic 
radiotherapy, hypo-fractionated 
stereotactic radiotherapy, high 
dose rate (HDR) brachytherapy, 
high dose rate (HDR) brachyther-
apy, low dose rate (LDR) bra- 
chytherapy, or stereotactic radio-
surgery (SRS). Despite numerous 
options, median survival post-re-
currence remains poor at 9– 
20 months [5]. The poor prognosis 
can be attributed to unique treat-
ment limitations, which include 
the infiltrative nature of tumor 
cells, failure of anti-glioma drugs 
to cross the blood–brain barri-
er, tumor heterogeneity and the 
highly metastatic and angiogenic 
nature of the tumor making cells 
resistant to chemotherapy. Com-
bination therapy approach is being 
developed against glioblastoma 
with new innovative combination 
drug regimens being tested in 
preclinical and clinical trials [6]. 
Despite the higher risk of distant 
brain lesions or subependymal 
spread, almost all patients develop 
tumor recurrence within or ad-
jacent to the primary tumor bed 
[7]. Even though gliomas are in-
filtrative with ill-defined margins, 
SRS has been reported to be an ef-
fective treatment modality [8–11]. 
The aim of our study to as-
sess the efficacy and toxicity of 
combination therapy approach 
using SRS and systemic treat-
ment (chemotherapy (ТMZ) and 
antiangiogenic therapy (BEV)) in 
recurrent GBM treatment.
2. Methods
We retrospectively reviewed 
21 patients (pts) who were treat-
ed for GBM recurrence at the 
State Institution “Institute of 
Neurosurgery named after acad. 
A.P. Romodanov of NAMS of 
Ukraine” (Kiyv, Ukraine) from 
January 2014 till March 2018. 
This study was approved by local 
Ethics Committee. We includ-
ed 8 females and 11 men with 
pathologically confirmed GBM 
who received comprehensive ini-
tial treatment and combination 
of SRS and systemic treatment 
for GBM recurrence. Median age 
at time of diagnosis was 52.4 
(29.7–69.3) years. The initial 
surgical treatment as gross total 
tumor resection was performed 
in 12 pts (57.1 %), subtotal resec- 
tion – 5 pts (23.8 %), biopsy – 
4 pts (19 %). Tumor MGMT pro-
moter methylation was seen in 
12 pts (57.1 %). In all cases adju-
vant radiation therapy (60 Gy in 
30 fractions) was used, 12 pts of 
them (57.1 %) – in combination 
with concurrent TMZ followed 
by 6-12 courses of TMZ accord-
ing R. Stupp protocol [3]. Pa-
tient’s demographic and clinical 
data were collected in Table 1.
Recurrent disease was treat-
ed by combination of SRS fol-
lowed by systemic treatment 
(chemotherapy (TMZ) + antian-
giogenic therapy (BEV)). SRS was 
performed by means of “Trilo-
gy” LINAC (“Varian”, USA) with 
a median dose and fractions of 
19.2 Gy (range, 12.0 –36.0) in 1 
to 5 fractions. Four pts (19 %) 
received 12 Gy in single fraction, 
5 pts (23.8 %) received 14 Gy 
in single fraction, 5 pts (23.8 %) 
received 24 Gy in 3 fractions, 7 
pts (33.3 %) received 25 Gy in 5 
fractions, treating 5 days/week. 
SRS was given combining IMRT 
and MLC Dynamic Arc dose de-
livery techniques. This approach 
provides maximal homogeneous 
dose distribution in target vol-
ume whereas minimal radiation 
exposure of normal tissue and or-
gans at risk (chiasma, brainstem, 
ect.). Further combined dose de-
livery technique allows to reduce 
time of treatment procedures to 
10-15 minutes per fraction. Due 
to the infiltrative characteristics 
of GBM we added safety margin 
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Abstract: Glioblastoma multiforme (GBM) is the most com-
mon primary malignant tumor of the central nervous system 
in adults. Dismal survival rates and poor prognosis for re-
current GBM patients still remains a challenging problem. 
Despite aggressive initial treatment, above 100 % GBM pa-
tients have development of recurrent diseases. Management 
of GBM recurrence is still debatable. The multimodality 
approaches using combination of stereotactic radiosurgery 
(SRS), cytostatic agents (Тemozolomide (TMZ)) and antian-
giogenic therapy (bevacizumab (BEV)) are often beneficial 
for such patients and may achieve survival improving.
Aim of research: to assess the efficacy and toxicity of combi-
nation therapy approach using stereotactic radiosurgery (SRS) 
and systemic treatment (chemotherapy and antiangiogenic 
therapy) in glioblastoma multiforme recurrence treatment.
Materials and methods: at the State Institution “Institute of 
Neurosurgery named after acad. A.P. Romodanov of NAMS 
of Ukraine” (Kyiv, Ukraine) 21 patients (pts) with GBM recur-
rence were treated (8 females and 11 men; median age at time 
of diagnosis 52.4 (29.7–69.3) from January 2014 till December 
2017. The initial surgical treatment as gross total tumor resec-
tion was performed in 12 pts (57.1 %), subtotal resection – 5 
pts (23.9 %), biopsy – 4 pts (19 %). 12 pts (57.1 %) were MGMT 
methylated and 9 pts (42.9 %) were MGMT unmethylated. In 
all cases adjuvant radiation therapy (60 Gy in 30 fractions) 
were used, 12 pts of them (57.1 %) – in combination with TMZ 
followed by 6–12 courses of chemotherapy (TMZ) according 
Stupp protocol. Recurrent disease was treated by SRS followed 
by TMZ + BEV. SRS was performed by means of “Trilogy” 
LINAC (“Varian”, USA) with a median dose and fractions of 
19.2 Gy (range, 12.0–36.0) in 1 to 5 fractions.
Results: median survival after initial diagnosis was 18.3 months, 
and 1- and 2-year survival rates of 85.7 % (18 from 21 pts) and 
38.1 % (8 from 21 pts) respectively. The median survival from 
the time of recurrence treatment was 8.3 months. The 6‐ and 
12‐months overall survival from SRS were 95.2 % (20 from 21 
pts) and 23.8 % (5 from 21 pts), respectively. Adverse radiation 
effects were noted in 6 (28.6 %) pts and were controlled with 
corticosteroids. Adverse events grade 1-2 related to the systemic 
therapy included hematological complications, fatigue, hyper-
tension and proteinuria were observed in 23.8 % (5 from 21 pts) 
without the occurrence of grade 3 events.
Conclusion: recurrent GBM management using combination 
of SRS, chemotherapy and antiangiogenic therapy is a prom-
ising multimodal treatment approach providing survival im-
proving whereas appropriate toxicity ratio. Further studies of 
combined treatment of GBM relapse are needed.
Keywords: glioblastoma multiforme recurrence, multimodality 
approaches, radiosurgery, temozolomide, bevacizumab, toxicity.
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(5–10 mm) around the contrast-enhancing target. The median 
Planning Target Volume (PTV) was 13.5 cm3 (range: 3.9– 
40.7 cm3). Seventeen (81 %) targets were located at the edge of 
the previous tumor resection cavity or at the area of previous 
biopsy.
Systemic treatment was applied after SRS (intravenous 
BEV 10–12 mg/kg once in 3 weeks up to 6 times; TMZ 150– 
200 mg/m² PO for 5 days, then 23-treatment free days until 
progression). 
Table 1
Patient’s characteristic: demographic and clinical data.
Number of patients N=21
Male 11/52 %
Female 8/38 %
Age at time of diagnosis (years):  
Median 52.4
Range 29.7–69.3
Initial surgical treatment:  
Gross total tumor resection 12/57.1 %
Subtotal resection 5/23.8 %
Biopsy 4/19 %
Histopathologic diagnosis Glioblastoma multiforme 21/100 %
MGMT Promoter Methylation Status:  
MGMT unmethylated 9/42.9 %
MGMT methylated 12/57.1 %
Adjuvant radiation therapy 21/100 %
Adjuvant chemotherapy 12/57.1 %
3. Results
Retrospective analysis of outcomes revealed median sur-
vival after initial diagnosis of 18.3 months, and 1- and 2-year 
survival rates of 85.7 % (18 from 21 pts) and 38.1 % (8 from 
21 pts) respectively.
The median survival from the time of recurrence was 
8.3 months.
The 6- and 12-months overall survival from SRS were 
95.2 % (20 from 21 pts) and 23.8 % (5 from 21 pts), respectively.
Adverse radiation effects were noted in 6 (28.6 %) pts and 
were controlled with corticosteroids.
Adverse events grade 1–2 related to the systemic therapy in-
cluded hematological complications, fatigue, hypertension and 
proteinuria were observed in 23.8 % (5 from 21 pts) without the 
occurrence of grade 3 events.
Survival and adverse events are represented in Table 2.
Table 2
Survival and adverse events
Parameter Score
Median survival after initial diagnosis 18.3 months
1-year survival 85.7 % (18 from 21 pts)
2-year survival 38.1 % (8 from 21 pts)
Median survival from the time of recur-
rence
8.3 months
6‐months overall survival from SRS 95.2 % (20 from 21 pts)
12‐months overall survival from SRS 23.8 % (5 from 21 pts)
Adverse radiation effects 28.6 % (6 from 21 pts)
Adverse events grade 1–2 related to the 
systemic therapy 
23.8 % (5 from 21 pts)
6. Discussion
GBM is an aggressive fatal disease with dismal median overall 
survival of 10 to 20 months. Even despite multimodality therapy 
and favorable pathologic features the vast majority of patients 
will recur in 6–8 months [10, 12]. Recurrence leads to progressive 
neurocognitive impairment and death in 3 to 9 months regardless 
re-operation [13, 14]. Current options for recurrence therapy are 
as follows: surgery, systemic therapy and re-irradiation. Combi-
nation therapy is an option for recurrence GBM recently being 
tested by some investigators [15, 16]. Our experience is consistent 
with latter and shows increase in survival rates with appropri-
ate toxicity compared to other approaches as described in the 
current literature. We report a median survival from the time 
of recurrence 8.3 months and the 6‐ and 12‐months overall sur-
vival from recurrence 95.2 % (20 from 21 pts) and 23.8 % (5 from 
21 pts), respectively. The weak points of our study are an absence 
of direct comparison with the control group, low number of pa-
tients included and lack of tumor molecular data.
Recurrent GBM management using combination of SRS, 
chemotherapy and antiangiogenic therapy is a promising mul-
timodal treatment approach providing survival improving 
whereas appropriate toxicity ratio. Further studies of combined 
treatment of GBM relapse are needed.
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